

Supplementary information:




Figure SI-01 Biodistribution %ID/g comparison in non-tumor bearing athymic nude mice (n = 2 female per time point) for radionuclide(s) ¹¹¹In- and ⁸⁹Zr- labeled panitumumab for the various time-points. Mice were i.v. injected 1.85 MBq and 5.3 MBq via tail-vein for ⁸⁹Zr-panitumumab and ¹¹¹In-panitumumab, respectively. The %ID/g uptake of panitumumab resulted in a good correlation $R^2 > 0.93$ $p < 0.0009$ between ¹¹¹In- and ⁸⁹Zr- labeled panitumumab.




Figure SI-02 Human organ dosimetry (mGy/MBq) comparison for radionuclide(s) ¹¹¹In- and ⁸⁹Zr-labeled panitumumab resulted in a good correlation $R^2 > 0.94$ $p < 0.0001$ between ¹¹¹In and ⁸⁹Zr, and also illustrating the higher organ dose of ⁸⁹Zr- than ¹¹¹In-labeled panitumumab due to the higher energy and emission rate (S-values) of ⁸⁹Zr.